Unmet Needs in the Era of Precision Medicine for RCC

Sandy Srinivas, MD


January 20, 2022

Sandy Srinivas, MD, identifies the unmet needs for patients with renal cell carcinoma and cites the importance of the KEYNOTE-564 trial, which is looking at the role of immunotherapy with pembrolizumab in patients with high-risk disease who have undergone a nephrectomy. Dr Srinivas notes that while we await final data on overall survival for this trial, it is an important step in identifying "the right therapy for the right patient."


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.